Loading...

We've got a brand new version of Simply Wall St! Try it out

Asia Cannabis

CNSX:ASIA
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ASIA
CNSX
CA$4M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Asia Cannabis Corp., an early-entry international agra-technology corporation, focuses on providing proprietary organic hybridization technology in Asia. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
ASIA Share Price and Events
7 Day Returns
4.8%
CNSX:ASIA
3.1%
CA Biotechs
1.2%
CA Market
1 Year Returns
-
CNSX:ASIA
-72.8%
CA Biotechs
-0.2%
CA Market
ASIA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Asia Cannabis (ASIA) 4.8% 0% - - - -
CA Biotechs 3.1% 10.9% -2.4% -72.8% -20.6% 26.7%
CA Market 1.2% 4.2% 1.5% -0.2% 8.4% 1.8%
1 Year Return vs Industry and Market
  • No trading data on ASIA.
  • No trading data on ASIA.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Asia Cannabis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Asia Cannabis. This is due to cash flow or dividend data being unavailable. The share price is CA$0.11.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Asia Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Asia Cannabis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ASIA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.04
CNSX:ASIA Share Price ** CNSX (2019-09-13) in CAD CA$0.11
North America Biotechs Industry PE Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 18.78x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 14.15x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Asia Cannabis.

CNSX:ASIA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ASIA Share Price ÷ EPS (both in CAD)

= 0.11 ÷ -0.04

-2.57x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Asia Cannabis is loss making, we can't compare its value to the North America Biotechs industry average.
  • Asia Cannabis is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Asia Cannabis's expected growth come at a high price?
Raw Data
CNSX:ASIA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.57x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 0.72x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.98x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Asia Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Asia Cannabis's assets?
Raw Data
CNSX:ASIA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.03
CNSX:ASIA Share Price * CNSX (2019-09-13) in CAD CA$0.11
Canada Biotechs Industry PB Ratio Median Figure of 32 Publicly-Listed Biotechs Companies 4.13x
Canada Market PB Ratio Median Figure of 2,452 Publicly-Listed Companies 1.44x
CNSX:ASIA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ASIA Share Price ÷ Book Value per Share (both in CAD)

= 0.11 ÷ 0.03

3.25x

* Primary Listing of Asia Cannabis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Asia Cannabis is good value based on assets compared to the CA Biotechs industry average.
X
Value checks
We assess Asia Cannabis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Asia Cannabis has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Asia Cannabis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Asia Cannabis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
23.9%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Asia Cannabis expected to grow at an attractive rate?
  • Unable to compare Asia Cannabis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Asia Cannabis's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Asia Cannabis's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ASIA Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.9%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 46.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ASIA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ASIA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 -1 -1
2019-03-31 0 -1
2018-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Asia Cannabis is high growth as no earnings estimate data is available.
  • Unable to determine if Asia Cannabis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ASIA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Asia Cannabis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ASIA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.04
2019-03-31 -0.03
2018-12-31 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Asia Cannabis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Asia Cannabis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Asia Cannabis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Asia Cannabis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Asia Cannabis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Asia Cannabis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Asia Cannabis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Asia Cannabis's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Asia Cannabis does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Asia Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Asia Cannabis's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Asia Cannabis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Asia Cannabis Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ASIA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -0.69 0.53
2019-03-31 -0.51 0.37
2018-12-31 -0.92 0.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Asia Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Asia Cannabis has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Asia Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Asia Cannabis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Asia Cannabis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Asia Cannabis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Asia Cannabis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Asia Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Asia Cannabis has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Asia Cannabis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Asia Cannabis has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Asia Cannabis Company Filings, last reported 2 months ago.

CNSX:ASIA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 1.23 0.00 1.19
2019-03-31 1.41 0.00 1.49
2018-12-31 0.42 0.00 0.48
  • Asia Cannabis has no debt.
  • Asia Cannabis has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Asia Cannabis has sufficient cash runway for 2.1 years based on current free cash flow.
  • Asia Cannabis has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 312.7% each year.
X
Financial health checks
We assess Asia Cannabis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Asia Cannabis has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Asia Cannabis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Asia Cannabis dividends.
If you bought CA$2,000 of Asia Cannabis shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Asia Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Asia Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ASIA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 58 Stocks 2.1%
Canada Market Average Dividend Yield Market Cap Weighted Average of 333 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Asia Cannabis has not reported any payouts.
  • Unable to verify if Asia Cannabis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Asia Cannabis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Asia Cannabis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Asia Cannabis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Asia Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Asia Cannabis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Asia Cannabis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Pinkman
COMPENSATION CA$0
AGE 62
TENURE AS CEO 0.4 years
CEO Bio

Mr. David Edward Thomas Pinkman, BA, LLB has been Interim CEO, President and Corporate Secretary of Asia Cannabis Corp since April 30, 2019. He has been an Interim Chief Executive Officer of Synstream Energy Corp. since August 21, 2017 until March 7,2016 and its Secretary until January 18,2018. Mr. Pinkman served as Chief Financial Officer of Synstream Energy Corp. since May 2007 umtil January 18,2018. He has been the Chief Operating Officer of International SoftRock Oil Company Limited since February 2015 and also serves as its Chief Financial Officer, Company Secretary and Director. Mr. Pinkman served as Vice President and Corporate Secretary at Red Rock Energy Inc. until June 17, 2017 and also served as its Interim Chief Financial Officer from March 10, 2016 to July 29, 2016. He served as the President, Chief Financial Officer and Secretary at SFR Energy Ltd. He served as Chief Executive Officer of SFR Energy Ltd. until January 5, 2015. He served as the Chief Executive Officer of Saccharum Energy Corp. until March 7, 2016. He served as the President of Explorator Resources, Inc. from September 2005 to January 26, 2007 and also served as its Chief Executive Officer until January 2007. He served as Vice President of PanWestern Energy Inc., until March 29, 2010 and served as its Chief Financial Officer from October 15, 2009 to March 29, 2010. He served as Vice President of Valeura Energy Inc., and served as its Chief Financial Officer until April 9, 2010. He served as Vice President of Powermax Energy Inc. from January 2001 to September 2005. From January 2001 to November 2001, Mr. Pinkman served as Vice President of International of Maxim Power Corp. (formerly, Jupiter Power International Inc.) (TSXV). He was Partner at the law firm Pinkman, McArdle, Barristers and Solicitors from June 1990 to March 2001. He was Called to the bar in 1985, as a lawyer he has practiced primarily in the areas of corporate and securities law. He served as an Executive Chairman of Jupiter Power International Inc. from August 31, 1993 to December 2000. He serves as a Director of Wild Rose Motocross Association, SFR Energy Ltd. He has been Director of Builders Capital Mortgage Corp. since March 28, 2013. He serves as a Director and officer of ITW Tank and Well Servicing Ltd. Mr. Pinkman served as a Director at Red Rock Energy Inc. since April 12, 2005 until June 7, 2017. Mr. Pinkman has served on the boards of a number of public and private companies carrying on business in the resource and other industries. He served as a Non-Executive Director of Renewable Power & Light plc from November 2, 2006 to September 24, 2007. He has been a Director of Synstream Energy Corp. since May 15, 2007. He served as Director of Worthington Energy, Inc. from January 2013 to August 4, 2014. He served as a Director of Renewable Energy Inc. He served as a Director of Explorator Resources, Inc. from September 2005 to January 26, 2007. He served as a Director of Powermax Energy Inc. from January 2002 to September 2005. Mr. Pinkman served as a Director of Celestial Energy Inc. since March 31, 2005. He served as a Director of PanWestern Energy Inc. from July 6, 2000 to March 29, 2010. He served as a Director of Cobalt Coal Ltd. He served as a Director of Jupiter Power International Inc. from August 1993 to December 2000. He serves as Vice President of Wild Rose Motocross Association, a non-profit association registered under the Societies Act. He became a member of the Law Society of Alberta in 1985. Mr. Pinkman has been Director of Asia Cannabis Corp. since January 9, 2018. Mr. Pinkman holds an LLB from the University of British Columbia in 1984 and a BA in English from the University of Calgary in 1980.

CEO Compensation
  • Insufficient data for David to compare compensation growth.
  • Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Asia Cannabis management team in years:

0.4
Average Tenure
60
Average Age
  • The average tenure for the Asia Cannabis management team is less than 2 years, this suggests a new team.
Management Team

David Pinkman

TITLE
CEO, President
AGE
62
TENURE
0.4 yrs

Vince Ghazar

TITLE
CFO & Director
COMPENSATION
CA$34K
AGE
47
TENURE
1.7 yrs

Ken McKinnon

TITLE
Consultant
AGE
60
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Asia Cannabis board of directors in years:

1.7
Average Tenure
52.5
Average Age
  • The average tenure for the Asia Cannabis board of directors is less than 3 years, this suggests a new board.
Board of Directors

David Pinkman

TITLE
CEO, President
AGE
62
TENURE
1.7 yrs

Vince Ghazar

TITLE
CFO & Director
COMPENSATION
CA$34K
AGE
47
TENURE
1.7 yrs

Igor Kovalchuk

TITLE
Director
AGE
49
TENURE
1.4 yrs

Jo Kingma

TITLE
Director
COMPENSATION
CA$102K
AGE
56
TENURE
1.8 yrs

Dwight Hudson

TITLE
Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Asia Cannabis individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
12. Aug 19 Buy Johannes Kingma Individual 09. Aug 19 09. Aug 19 42,000 CA$0.09 CA$3,948
03. Jul 19 Buy Inplanta Company 28. Jun 19 28. Jun 19 2,500,000 CA$0.05 CA$130,807
X
Management checks
We assess Asia Cannabis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Asia Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can We See Significant Insider Ownership On The Asia Cannabis Corp. (CNSX:ASIA) Share Register?

Taking a look at our data on the ownership groups (below), it's seems that institutions don't own shares in the company. … Check out our latest analysis for Asia Cannabis CNSX:ASIA Ownership Summary, August 1st 2019 What Does The Lack Of Institutional Ownership Tell Us About Asia Cannabis? … Insider Ownership Of Asia Cannabis While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Company Info

Description

Asia Cannabis Corp., an early-entry international agra-technology corporation, focuses on providing proprietary organic hybridization technology in Asia. Its products are used in the planting, growth, and harvesting of new and valuable hemp strains and related crops. The company was incorporated in 2017 and is based in Calgary, Canada.

Details
Name: Asia Cannabis Corp.
ASIA
Exchange: CNSX
Founded: 2017
CA$3,987,181
36,247,100
Website: http://asiacannabiscorp.com
Address: Asia Cannabis Corp.
1015 – 4th Street S.W.,
Suite 730,
Calgary,
Alberta, T2R 1J4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ASIA Common Shares Canadian National Stock Exchange CA CAD 24. Jan 2019
Number of employees
Current staff
Staff numbers
0
Asia Cannabis employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/15 00:45
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/08/19
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.